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Introduction
Cancer of the kidney is expected to affect almost 100.000 patients in the United States and 
European Union in 2010[1;2]. Renal cell carcinomas (RCC) refer to cortically derived 
tumors of the renal parenchyma and encompass a heterogeneous group of cancers[3]. 
Advances in basic research aimed at defining pivotal molecular events in the development of 
these different entities has shown that renal cancers can be subdivided based on genetic 
profiles. Moreover, knowledge of underlying molecular characteristics identified the 
vascular endothelial growth factor (VEGF) and the mammalian target of rapamycin (mTOR) 
pathways as fundamental to the biology of clear cell RCC. This biologic insight provided a 
rationale for targeting these growth factor signaling pathways in RCC.
Basic science in RCC is a vast area therefore we will focus on four areas of research that 
were felt most relevant for renal cancer and are not discussed in-depth in other chapters: the 
molecular basis of renal cancer, targeted therapies, renal cancer and immunity, and genetic 
factors and RCC. Finally, it is important to note that great majority of basic research in RCC 
is focused on clear cell RCC given the high prevalence of this histological subtype. 
Additionally, while the vast majority of studies have been performed on material from 
primary lesions, future studies should consider examination of metastatic lesions as well.
The molecular basis of renal cancer
Historically, four main histological renal cancers were recognized in the Heidelberg 
classification: clear cell Renal Cell Cancer (ccRCC, 60–80%), papillary RCC (10–15%), 
chromophobe RCC (~5%) and renal oncocytoma (~5%)[3;4] Recently, translocation 
linked[5;6], mucinous tubular and spindle type RCC[7] and tubulocystic carcinoma[8] (all 
comprising <1% of cases) have been added to this list. It is now clear that these 
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morphological subtypes represent highly dissimilar diseases in both genetics and clinical 
behavior, and thus may or may not be variants of a common cancer or common cell of 
origin.
The biology of the von Hippel-Lindau (VHL) gene product, pVHL, and its regulation of the 
hypoxia inducible factor (HIF) family of hypoxia-regulated transcription factors, is tightly 
linked to ccRCC biology. The discovery of the VHL gene, and its association with the VHL 
syndrome of central nervous system hemangioblastomas, pheochromocytoma/
paraganglioma, and ccRCC, in 1993[9] quickly led to the discovery that VHL mutation is 
also tightly associated with sporadic ccRCC, detected in up to 90% of tumors[10–13]. The 
loss of VHL leads to the loss of regulation of HIF family members HIF1α, HIF2α[14–18], 
and HIF3α[19], which is further composed of several splice variants. Xenograft studies have 
demonstrated that restoration of pVHL expression or suppression of deregulated HIF2α 
impairs the growth of these tumors[20;21].
Papillary RCC, chromophobe RCC and renal oncocytoma are less dominated by mutations 
in a single gene. Mutations in c-met have been associated with familial papillary type 1 
RCC, but only in a subset of sporadic papillary RCC, and is thus less dominant than VHL is 
for ccRCC[22]. A more rare, but also highly aggressive type of papillary type II renal cell 
carcinoma has been associated with mutations in the fumarate hydratase gene [23], although 
the relevance of this mutation in sporadic disease is unknown. Heterozygous knock-out of 
the gene implicated in the Birt-Higg-Dubé (BHD) syndrome in mice leads to the 
development of renal cysts and three different histological types of renal tumors, similar to 
human BHD which is closely associated with familial chromophobe RCC, but predisposes 
to other histologies as well [24].
In spite of the tight correlation of ccRCC with inactivation of VHL, the effect on HIF 
deregulation is not uniform: variant mutations in VHL may contribute to imbalances of 
HIF1α and HIF2α deregulation, leading to distinct effects on cell growth[25;26]. In a 
strategy to determine whether tumors could be defined based upon the most studied and 
understood pathway in RCC, gene expression profiles were linked with VHL mutation 
analysis and expression characteristics of the HIFs[27]. In this study, 160 ccRCCs were 
classified as VHL mutant or wild type and according to HIF protein expression. VHL 
mutant, HIF1 and HIF2 expressing tumors (H1H2) overexpressed the Akt/mTOR pathway, 
while VHL mutant tumors expressing solely HIF2 (H2 tumors) replicated more rapidly, 
marked by overexpression of Ki-67, which other groups have identified as a poor-risk 
marker[28]. ccRCC can thus be characterized as H1H2 or H2, with dramatically differing 
effects on tumor cell proliferation and C-myc regulation[27]. Recent evidence suggests that 
the H2 tumors may be derived from H1H2 tumors that lose HIF1α in a subset of tumors, 
suggesting a potentially selective pressure to lose the HIF1α gene during tumor 
progression[29]. These insights potentially narrow the key tumorigenic events within the 
VHL/HIF axis.
Besides VHL loss and HIF activation, major efforts have yet to identify a simple linear 
progression of genetic lesions accounting for the gains in aggressiveness in RCC[30–34]. 
Two recent ccRCC cytogenetic studies lend clues to understanding this progression. One 
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study performed both single nucleotide polymorphism (SNP) analysis and gene expression 
analysis on sporadic ccRCC and tumors from patients with VHL disease[30]. Importantly, 
this study demonstrated that tumors from sporadic and VHL-disease ccRCC tumors have 
overall similar profiles, but sporadic tumors are more heterogenous and contain a higher 
number of genetic events per tumor, but they cannot be distinguished using unsupervised 
analysis of gene expression data. In a prospective analysis of 282 ccRCC patients with up to 
108 months of follow-up using traditional cytogenetic karyotyping techniques[32] 
chromosomal loss at 3p (the genomic home of the VHL gene) was significantly associated 
with improved disease-specific survival, while losses of 4p, 9p and 14q were significantly 
associated with reduced disease-specific survival, but the specific genes in these regions 
implicated in causing the poor prognosis remain to be characterized.
The first whole sequencing study in ccRCC confirmed that considerable genetic 
heterogeneity exists in ccRCC [29] emphasizing that even though the vast majority of 
ccRCC contain mutated VHL most likely every tumor has a unique gene signature. This 
study also substantiated findings in multiple mouse knock-out studies and a zebrafish study 
which demonstrated that VHL mutations/knock out alone is insufficient to produce ccRCC 
and that additional genetic events are required [35;36].
Although unable to cause sporadic ccRCC alone, the presence and type of VHL mutations in 
tumors have been consistently considered as possible biomarkers. Cowey, et al, recently 
reviewed its potential in prognosis and prediction[37]. Further research is still required to 
establish VHL’s efficacy as a biomarker, but given the frequency of its inactivation, more 
opportunities to understand the heterogeneity of this disease may lie in exploration of 
downstream factors. When VHL is inactivated and HIF expression constitutively stabilized, 
a host of other genes which make up various components of the hypoxia response are 
transcriptionally upregulated (reviewed in[38]). It remains to be determined which of these 
factors or pathways most significantly contributes to the formation or maintenance of 
ccRCC’s malignant phenotype. One HIF target, the vascular endothelial growth factor 
(VEGF), has been found to be significantly upregulated in kidney tumors compared to its 
elevated expression in many other cancers. As a prognostic biomarker, VEGF has not been 
proven to be valuable, but may be predictive of response to VEGF targeted therapy, as 
described below.
In order to identify more effective biomarkers and further understand the underlying biology, 
several different groups performed gene expression analyses on ccRCC tumor samples. 
Table 1 gives an overview of these studies. One of the initial expression profiling studies 
examined 29 ccRCC tumors, identifying 51 genes that could classify tumors based on 5 year 
disease-specific survival[39]. This study verified the possibility that gene expression profiles 
could be used to predict outcome in ccRCC, but remains to be validated or defined by 
biological parameters that may account for this difference in disease activity. One study of 
51 tumor samples identified vascular cell adhesion molecule-1, VCAM-1, as a prognostic 
biomarker [40], which has subsequently undergone retrospective validation [41;42]. 
Importantly, high expression of this molecule predicted for better overall survival in both 
clear cell and papillary tumors, suggesting that VCAM-1 expression may generally indicate 
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tumor cells with lower metastatic potential. The further implications for sensitivity to 
antiangiogenic therapy are not yet known.
Several gene signatures for RCC progression, for example three genes (caveolin 1, lysyl 
oxidase, and annexin A4) have been identified as associated with RCC aggression and/or 
survival[43] [44]. Similarly, survivin was shown to independently predict clear cell 
progression and risk of death [45][46]. Finally, the largest study, analyzing 177 clear cell 
tumors, identified 340 transcripts (including VCAM-1) significant in multivariate analysis 
with stage, grade and performance status[47][48].
While the above studies focused on clinical endpoints in their analyses, many started with an 
unsupervised analysis to get a general understanding of the data. The study that identified 
VCAM-1 as a prognostic biomarker saw the presence of potentially two subgroups within 
the stage IV tumors, with survival differences[40]. This suggests that molecular features 
beyond clinical staging could provide informative data in understanding even metastatic 
tumor behavior. The group of Zhao, et al. examined their 177 tumors using 3,674 genes also 
observed two larger groups of ccRCC, with significant survival differences as well as 
predicted biological pathway distinctions[47]. These studies helped to set the stage for 
further delineation of subgroups within ccRCC.
Two other studies stand out as being predominantly geared toward identifying the inherent 
subgroups and underlying biological differences of ccRCC. One group first looked at 16 
ccRCC tumors and saw that there seemed to be two types of clear cell, one that more highly 
overexpressed metabolic genes and the other extracellular matrix/cell adhesion genes[49]. 
Most recently, a bioinformatic technique called unsupervised consensus clustering was used 
on 48 tumors to identify two subtypes of ccRCC, ccA and ccB, distinguished by fewer than 
120 probes[50]. Validating these results in the Zhao, et al., data set of 177 tumors, patients 
with ccA tumors have a marked survival advantage over those with ccB tumors. 
Additionally, this dataset validates the characteristics that ccA tumors display a profile of 
altered metabolism, whereas ccB tumors display characteristics of wound healing and 
epithelial to mesenchymal transition.
Finally, one study focused entirely on metastases[51], finding that late occurring metastases 
more highly expressed genes involved in angiogenesis, cell migration and adhesion. 
Additionally, genes related to cell division and cell cycle were overexpressed in samples 
from patients with multiple metastases, indicating that the presence of more metastases 
might be caused by an increased growth potential.
All of the potential biomarkers emerging from the gene expression studies require removal 
and processing of at least part of the tumor. Plasma serum proteins have traditionally been 
studied to find non-invasive diagnostic markers for the presence of ccRCC as compared to 
normal or benign renal tissue. Currently, there are no circulating tumor markers available for 
clinical use in management of RCC. Several molecules have been studied as candidates for 
diagnosis of RCC: In clear cell RCC the results with VEGF and VEGFR have been 
contradictory[52;53], and these markers might be more suitable as predictive than as 
diagnostic markers. Recent studies have shown elevated CAIX levels in ccRCC patients[54], 
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with a significant association between CAIX serum levels and occurrence of metastases[55]. 
Furthermore, in patients with localized disease an elevated CAIX level predicts the 
recurrence and is correlated with a shorter PFS. Again, there is not a complete concordance 
with tissue results. Other markers related to tumor biology like MMP-7, CD95, bFGF, 
hepcidin-25, Il-10 or IL-6 showed promising results as possible biomarkers for RCC[56–
60], but these markers need to be validated in separate studies.
Because of the complexity of the tumor development and progression, identification of 
complex protein signatures is more promising. High throughput technologies like MALDI 
(Matrix-assisted laser desorption/ionization) or SELDI (Surface Enhanced Laser Desorption/
Ionisation) allow the analysis of the whole proteome of many samples in a short time with 
high sensitivity. SELDI-TOF-MS (Time of Flight Mass Spectrometry) has especially been 
used to define prognosis related profiles. Unique protein signatures of tumor patients 
compared to normal controls with high sensitivity (70–87%) and specificity (89.9–92%) 
have been described[56–63]. One of the candidate proteins, SAA1, was identified by 3 
groups[61;64;65]. In all published studies, elevated SAA1 concentration correlated with 
metastasis, poor prognosis and shorter survival[61;64–66], even though different cut-off 
values were used. Independent studies are needed to substantiate the value of SAA1.
Finally, an 831 tumor tissue microarray study analyzed 15 proteins that are associated with 
the pVHL and phosphatase and tensin homologue (PTEN) pathways[67]. Surprisingly, while 
pVHL and phospho-mTOR staining correlated inversely with tumor stage and grade, neither 
protein correlated with survival. Within the intermediate stage tumors (pT2 and pT3), tumors 
with p27 and CAIX expression associated with improved outcome. This study suggests that 
the dysregulation of several independent pathways are crucial for tumor progression, 
corroborating the sequencing study by Dalglish, et al.[29].
MicroRNA, 21–23 nucleotide segments of single-stranded non-coding RNA, have now been 
implicated in tumorigenesis of many cancers, even being identified as potential prognostic 
biomarkers in several of these (reviewed in [68]). The aberrant expression of these non-
coding RNAs can provide a powerful method of epigenetic tumor regulation, as an 
individual microRNA can alter the expression of many target genes. In RCC, various studies 
have identified various individual or panels of microRNAs that are differentially expressed 
between normal renal tissue and tumor or between histological subtypes[69–76]. The 
identification of relevant targets of these tumor associated microRNAs are just becoming 
realized[74]. MicroRNAs can be easily extracted from formalin fixation, paraffin embedded 
tissue, and blood. The ability to easily use non-invasive measures to identify a stable target 
makes microRNAs a very attractive biomarker for diagnostic, prognostic, and predictive 
purposes.
A large number of potential biomarkers have emerged from all these gene expression 
studies. Encouragingly, trends are beginning to emerge between studies. The next important 
step will be bringing these potential biomarkers and biomarker profiles to the clinical arena.
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Targeted therapies in RCC
The increased understanding of the fundamental disease biology of RCC has been translated 
into the development of therapies with inhibitory activity against the implicated pathways, 
particularly the VEGF and mTOR pathways. A number of tyrosine kinase inhibitors (TKI) 
have now been registered for treatment of metastatic RCC (mRCC) (sunitinib, sorafenib, 
pazopanib) and more TKI (e.g. axitinib, tivozanib) are being developed. The rapid and 
simultaneous emergence of several active compounds has far outpaced the ability to 
critically understand precise mechanisms of response and resistance[77].
Surprisingly, the TKI were clinically implemented with very few preceding pre-clinical 
studies. For example, the cross-reactivity of TKI with non-target (non-VEGF-receptor) 
TK[78] was established after clinical implementation and preclinical studies in various 
animal models demonstrated stabilization or regression of xenografted tumors (mostly in 
non-RCC models). The rationale to study this new category of drugs in RCC patients was 
based on theoretical considerations that these TKI attacked pathways essential in RCC 
biology and, therefore, might be appropriate new drugs for RCC therapy. Indeed, the effects 
of TKI in RCC patients are impressive, with objective response rates as high as 45% 
(reviewed by e.g., Rini et al. [79]), but treatment is often accompanied by many side effects 
requiring dose reduction or cessation of treatment.
TKI treatment of RCC patients leads to a massive destruction of the tumor vasculature with 
concomitant tumor necrosis. Whether RCC cells themselves are targeted remains 
uncertain[80]. At pharmacological relevant doses no effect on tumor cells was observed[80] 
and there is evidence that tumor co-option occurs, i.e., tumor growth along larger mature 
vessels, permitting tumors to escape TKI treatment. Additionally, resistance to existing 
VEGF blocking agents may include upregulation of HIF- and/or non-HIF-mediated 
angiogenic proteins or inadequate target inhibition. mTOR therapy resistance may involve a 
compensatory increase in upstream elements leading to HIF production[77].
Obviously, predictive biomarkers for response to TKI in mRCC patients are urgently needed, 
and some have been described. Serum from patients with clinical response or progression 
was screened by cytokine arrays to discover that TNF-alpha and MMP-9 levels remained 
low in responders[81]. Additionally, high levels of these proteins in the serum correlated 
with decreased overall survival. In another study, low serum levels of sVEGFR-3 and 
VEGF-C corresponded with longer progression free survival (PFS) and objective response 
rate in bevacizumab-refractory mRCC[82]. A third study suggested that large changes in 
serum VEGF, sVEGFR-2 and sVEGFR-3 levels corresponded with tumor response[83], and 
a fourth study found a correlation between fold-increase of serum VEGF and clinical 
benefit[84]. All of these potential predictive biomarkers require external validation in larger 
sample sizes, but suggest that serum may prove to contain cogent markers of survival and 
response.
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RCC and the immune system
There is increasing evidence that TKI treatment leads to alterations of the immune status of 
RCC patients[85;86]. Sunitinib can reverse myeloid-derived suppressor cell induced immune 
suppression, but other studies indicate that Sunitinib can inhibit the proliferation of primary 
human T cells from normal healthy volunteers as well as from RCC patients[87]. Moreover, 
sunitinib treatment appears to reverse Th1 suppression and impairs NK function. Similarly, 
sorafenib treatment impairs NK activity and cytotoxicity at pharmacological levels[85]. 
Also, sorafenib treatment leads to a decrease of Treg in primary lesions and Treg levels 
decrease to normal levels after sorafenib treatment. Whether the immune component is 
important and might be used to our advantage in designing combination therapies is an 
uncharted field[86].
It is important to realize that RCC tumors develop in immune competent hosts and that these 
tumors have escaped from immune surveillance and immune editing leading to tumor cells 
that are resistant to immune-system mediated destruction[88]. Nevertheless, to date, 
immunotherapy is the only treatment that can consistently induce durable complete clinical 
responses in mRCC[89].
Several studies have demonstrated the ability of tumor infiltrating lymphocytes (TIL) to 
induce tumor response in mRCC with objective response rates between 0 and 25 %, with 
concomitant infusion of IL-2[90–95]. At UCLA, patients with largely advanced and 
metastatic disease received a combination of TIL/CD8+ and IL-2. Overall, 9.1 % of patients 
achieved CR while 25.5% had a PR showing the potential of TIL in mRCC[94]. Taken 
together these studies demonstrated the need of using highly selective and specific activation 
methods of effector cells in order to achieve a meaningful antitumor immune response. 
Unlike melanoma, where specific T-cell clones against well-defined tumor epitopes can be 
frequently generated, T-cell clones that specifically recognize kidney cancer tumor antigens 
are hard to generate. The proof of concept of isolating these clones and successfully treat 
patients with mRCC has however been well established. On the other hand, given the in vitro 
work needed to isolate TIL, this approach still needs to prove that it induces better clinical 
responses than HD-IL2 alone.
Side studies of clinical trials with dendritic cells loaded with cell lysates, peptides, or RNA 
or Treg depletion have demonstrated the induction of specific T cell responses, but no clear 
correlation between clinical benefit and the occurrence of a immune reaction was 
found[96;97]. There is evidence that various factor hamper an anti-tumor response: defective 
CD8 signaling, a Th2-bias, and elevated levels of gangliosides from T cells are associated 
with T cell dysfunction[98;99]. Basic research aimed at understanding the relation between 
RCC and immune cells have revealed an increasingly complex picture with many players. 
Cross-talk between RCC and dendritic cells (DC), Treg, CD4+, CD8+, NK-cells, γδT cells, 
NK-like T cells, and Myeloid Derived Suppressor Cells, have been described[100]. The 
plasticity of cells from the immune system is extraordinary and the tumor milieu plays a 
pivotal role and can greatly influence the outcome.
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In recent studies, efforts were poised at gene-modified T-cells[101] and multimodality 
immune-based strategies[102]. Gene-modified T cells in melanoma has shown interesting 
results with two CR [103]. For RCC, infusion of gene-modified T cells with CAIX 
specificity lead to liver toxicity, probably due to destruction of bile epithelial cells that also 
express CAIX[101]. Although this demonstrated that the gene-modified did exert the desired 
specificity, the observed toxicity also highlights the potential problems of this approach: 
extraordinary tumor specificity appears to be of utmost importance. In the multi-modality 
immune-based strategy the CA9 and GMCSF genes were inserted in an adenovirus genome 
to infect DC which allowed the expression of the GMCSF/CA9 fusion protein[102]. 
Overexpression of the fusion protein in DC through adenoviral infection CA9 specific T 
cells could be generated with toxicity against RCC. Hence, this new strategy combines many 
immunotherapy approaches: 1) the immunostimulatory effects of cytokines; 2) the vaccine 
capabilities of DC and; 3) the specific antitumor activity generated by tumor antigen gene 
delivery in APC. Indeed, the CA9-GMCSF/DC based vaccine is an example of the new 
multimodality immune-based strategies that may enhance the well-established potentials of 
immunotherapy in RCC.
The effectiveness of tumor vaccines has been shown in many animal models. However, 
translation to the clinic has proven difficult, possibly because in these model systems 
naturally occurring tumors have not been studied, thereby avoiding tumor surveillance and 
tumor editing. Thus, the concept is tested in immune competent hosts that are vaccinated 
with peptides or tumor homogenates and challenged with viable tumor cells or, alternatively, 
vaccination strategies are tested in animals with established tumors. Initial tumor vaccines 
were based on total tumor cell lysates that were injected to the patients (autologous tumor 
cell vaccines). However, new strategies using genetically modified tumor cells, antigen 
presenting cells (APC) or tumor specific peptides have been developed to increase the 
specificity of the response. Two phase-III clinical trials that have used autologous cell lysate 
or peptides to prevent recurrence in high-risk RCC patients have been published[104;105]. 
Jocham et al. have reported a statistically significant increase in 5-year PFS (77.4 vs 67.8%, 
p=0.0204) for the vaccine group in high-risk non-metastatic RCC patients. More recently, 
Wood et al. published a similar study in high-risk non-metastatic patients using heat shock 
protein derived peptide vaccines and did not observe a statistical difference in PFS (p=0.51). 
However, secondary analysis did show an almost statistically significant PFS survival when 
only stage I and II patients where included (p=0.056). Therefore, vaccine approaches show 
great promise in preventing recurrence after nephrectomy but the subgroups of patients that 
would beneficiate from such therapy still need to be determined.
Genetic factors and RCC
Epidemiological studies have conclusively identified three risk factors for the development 
of RCC: hypertension, obesity and smoking[106–108]. Furthermore, there is evidence that 
genetic factors influence susceptibility to RCC; for instance, the life-time risk increases 
approximately two-fold for those with a first-degree relative with RCC[109]. Thus far, 
candidate gene studies have not yielded notable candidate genes. In a recent genome-wide 
association study (GWAS) of RCC three susceptibility loci on chromosomes 2p21 (EPAS1), 
11q13.3 and 12q24.31 (SCARB1) were identified (Purdue et al, submitted). The findings 
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from the GWAS provided further evidence that EPAS1 (HIF2α) is a key gene in RCC 
development, but additional studies are needed to identify the functionally relevant common 
variants associated with increased risk.
Up to now little attention has been paid to inter-ethnic variability or individual differences, 
whereas this is an important aspect in the current TKI era. Patients of afro-american descent 
have higher incidence rates and lower survival rates compared to all other races, also when 
diagnosed with localized disease. In contrast, Asian/Pacific Islander patients have lower 
incidence rates and higher survival rates than all the other ethnicities[110]. Furthermore, 
response to treatment and frequency of severe toxicity is related to ethnic origin, most likely 
due to different pharmacokinetics and not the genetic nature of the disease. Sunitinib, 
sorafenib and pazopanib have been associated with significant toxicity profiles which vary 
widely. Higher toxicities during cytotoxic chemotherapy have been reported in patients 
enrolled Japanese trials compared to patients in American or European trials[111]. Ethnic 
differences in hematological toxicity have been attributed to the varying activities of drug –
metabolizing enzymes and transporters that are mainly associated with polymorphisms in 
the promoter and coding regions of these enzymes[111]. In a phase II study assessing the 
efficacy and safety of sunitinib in Japanese patients, the incidence of hematological adverse 
events was numerically higher than those previously reported in western trials, however the 
AUC values for sunitinib were similar in both groups[112].
In the only pharmacogenetic study published until now, 31 single nucleotide polymorphisms 
in 12 candidate genes, together with several non-genetic variants, were analyzed for a 
possible association with toxicity[113]. Encouragingly, particular haplotypes (most notably 
by polymorphisms in CYP1A1) could be correlated to sunitinib-related toxicity. Because 
race-related differences in the frequency distribution of four genetic polymorphisms in the 
CYP1A1 P450 enzyme genes have been identified between Japanese and Caucasian 
populations, this may partly explain the inter-ethnic differences observed[114].
Conclusions
In the last decade, great strides have been made in the understanding of molecular 
mechanisms underlying renal cell carcinoma patients. The state-of-the-art has clearly led 
this field to the enviable position of having a range of molecularly targeted therapies. 
Nevertheless, despite the clear improvement in the therapeutic options for mRCC patients, 
therapies targeting the tumor cells themselves are highly desirable. Better models, closer 
resembling the natural course of renal cancer are needed. It is foreseen that through 
integration of various high-throughput platforms personalized cancer treatment for renal cell 
carcinoma patients is possible. There are further improvements expected on the horizon: 
recent effort have made progress toward using formalin-fixed paraffin-embedded tissues for 
molecular analyses (including DNA and RNA recovery), which will permit studies on 
enormous archives of existing specimens [115] including metastatic lesions, a hitherto 
understudied area; mature profiles of protein and nucleic acid biomarkers will help us to 
define the spectrum of tumors that lie under the umbrella of ccRCC; and a future unmapped 
territory of genetic mutations to explore that may provide more tools and answers to the 
Oosterwijk et al. Page 9













questions we ask. There is great hope for the future of renal cell carcinoma treatment, and it 
will be exciting to see what new advances will be made in the decade to come.
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